GLFD Guilford Pharmaceuticals (MM)

Guilford Pharmaceuticals to Announce Third Quarter 2003 Financial Results on Thursday, November 6, 2003 BALTIMORE, Oct. 30 /PRNewswire-FirstCall/ -- Guilford Pharmaceuticals Inc. will announce its third quarter 2003 financial results on Thursday, November 6, 2003 before the opening of the U.S. financial markets. The company will also host a conference call and live audio webcast at 11:00 a.m. E.S.T. following the announcement. During this call, Guilford's management will discuss the financial results and other business for the quarter. The press release and live webcast can be accessed by going to the Investor Relations section of Guilford's website at http://www.guilfordpharm.com/. Following the webcast, an archived version of the call will be available until November 20, 2003. To participate in the live conference call, U.S. residents dial (888) 425-2604, international callers (706) 679-8253. An audio replay of the conference call will be available for 48 hours beginning at approximately 2:00 p.m. E.S.T. on November 6, 2003 through 2:00 p.m. November 8, 2003. To access the replay, U.S. residents should dial 1-800-642-1687, (int'l callers 706-645-9291), reservation number 3669705. Guilford Pharmaceuticals Inc. is a fully integrated pharmaceutical company engaged in the research, development and commercialization of products that target the hospital market. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist used for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and post-prostatectomy erectile dysfunction. Contact: Guilford Pharmaceuticals Inc. Stacey Jurchison 410.631.5022 DATASOURCE: Guilford Pharmaceuticals Inc. CONTACT: Stacey Jurchison of Guilford Pharmaceuticals, +1-410-631-5022, Web site: http://www.guilfordpharm.com/ Company News On-Call: http://www.prnewswire.com/comp/112882.html

Copyright